Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of Sativex for cancer related pain (GWCA0958)
This trial looked at Sativex for cancer pain that couldn’t be controlled with other strong painkillers.
This trial was open for people to join between 2010 and 2013. These results were published in a journal in 2018.
This trial is very similar to the GWCA0962 trial and the results of which are on the database.
More about this trial
It is quite common for people with advanced cancer to have pain. Advanced cancer means the cancer has spread or come back since it was first treated.
There are different ways to treat cancer pain, including strong painkillers called opioids. But sometimes, even opioids cannot completely control the pain.
Researchers were looking for ways to help people in this situation.
In this trial, they looked at a drug called Sativex which contains cannabinoids from the cannabis sativa L. (marijuana) plant. The main cannabinoids in Sativex are tetrahydrocannabinol (THC) and cannabidiol (CBD) along with other minor cannabinoids and non-cannabinoid components.
In the UK, Sativex is already used to relieve the muscle spasms, stiffness and weakness caused by a disease called multiple sclerosis. It can also work as a painkiller. The aims of this trial were to:
- see if Sativex helped to relieve cancer related pain that wasn’t completely controlled with opioid drugs
- learn more about the side effects
Summary of results
The team found that Sativex didn’t work better than a dummy drug.
About this trial
This was a phase 3 trial. 397 people took part.
It was a randomised trial. Everyone was put into 1 of 2 groups. Neither they nor their doctor chose which group they were in.
- 199 people were to have Sativex
- 198 people were to have a dummy drug (
Of the 397 people, 291 completed treatment in the trial:
- 141 in the Sativex group
- 150 in the dummy drug group
When the researchers looked at how well treatment worked they included all 397 people. This is an
Everyone continued to have their opioid drugs during the trial. They took Sativex or the dummy drug as a spray into the mouth.
The trial lasted for 5 weeks. During the first 2 weeks people could increase the number of sprays each day until:
- it controlled their pain or
- there were unacceptable side effects from the spray
The most number of sprays they could have each day was 10.
During the trial they completed questionnaires. The questions asked about:
- their pain
- how often they used the spray
- did their dose of opioid treatment change
quality of life
- any side effects
- how satisfied they were
The average number of sprays people took each day was:
- 7 sprays (7.3) in the dummy drug group
- 6 sprays (6.4) in the Sativex group
After 5 weeks of treatment the team looked at how well it worked. They found that Sativex was better than the dummy drug at controlling people’s cancer pain. But this wasn’t
Towards the end of the 5 weeks for those who were taking Sativex there was an improvement in their sleep.
Doctors also felt that those people who took Sativex were in general better.
The side effects of Sativex were:
- feeling or being sick
- loss of appetite
The trial team concluded Sativex wasn’t any better than a dummy drug to help control pain caused by advanced cancer. But there may be other benefits for these people when they take Sativex.
The trial has also helped the team learn more about cancer pain which will be very useful in the future for other trials.
They think it is reasonable to do further trials using Sativex. Especially for people with certain cancer pain types who are taking small doses of opioids to control their cancer pain.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Marie Fallon
NIHR Clinical Research Network: Cancer